Medscape Coverage from
Digestive Disease Week (DDW) 2017
COMMENTARY
Early Look at Two New Hepatitis C Pangenotypic Therapies
Digestive Disease Week (DDW) 2017
Nancy S. Reau, MD
Despite the incredible evolution in hepatitis C (HCV) therapeutics, much remains to be done to affect the incidence, prevalence, and morbidity caused by this silent but curable disease. Several presentations at the recent Digestive Disease Week (DDW) meeting offer new perspectives in screening, reinfection, and therapy.
Risk-based screening was the primary way to identify individuals with chronic HCV until 2012, when the Centers for Disease Control and Prevention released recommendations to screen Americans born between 1945 and 1965, the birth cohort with the highest prevalence of chronic HCV and the most chronically infected with advanced fibrosis.
Continue reading.....
No comments:
Post a Comment